Key Details
Price
$90.85Last Dividend
$0.70Annual ROE
7.20%Beta
0.31Events Calendar
Next earnings date:
Feb 18, 2025Recent quarterly earnings:
Nov 19, 2024Recent annual earnings:
May 23, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
Dec 27, 2024Next split:
N/ARecent split:
Sept 27, 1999Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
In the latest trading session, Medtronic (MDT) finished at $91.99, showing an increase of 0.63% compared to the day before.
In the latest trading session, Medtronic (MDT) finished at $91.99, showing an increase of 0.63% compared to the day before.
If you invest in dividends, I can see why you would do that. Dividend-paying stocks provide three benefits: if the company is doing well and expanding, its stock price is likely to rise. Additionally, shareholders receive cash payments through dividends.
When purchasing income stocks, the company's core business is often the most important aspect to think about, even more than the dividend yield. Companies with high yields might seem appealing, but these yields can sometimes be unreliable.
In the most recent trading session, Medtronic (MDT) finished at $90.19, which is an increase of 1.05% compared to the previous day.
We have put together a list of the 30 Most Important AI Stocks according to Blackrock. In this article, we will examine how Medtronic plc (NYSE:MDT) compares to other AI stocks. In the third quarter of 2024, the investment giant Blackrock shared their views on the market outlook for artificial intelligence.
Medtronic (MDT) finished the latest trading session at $85.40, which represents a 0.18% increase from the previous day's closing price.
Medtronic plc (NYSE:MDT) will hold its 43rd Annual J.P. Morgan Healthcare Conference Call on January 13, 2025, at 5:15 PM ET. The company will be represented by several key participants, including CEO Geoff Martha, EVP Sean Salmon, Interim CFO Gary Corona, and EVP Que Dallara. Robbie Marcus from JPMorgan will also be part of the conference call.
A national coverage analysis is being conducted for a new, minimally invasive treatment for high blood pressure, which is a significant public health concern. Medtronic has announced that the Centers for Medicare & Medicaid Services (CMS) will review and create a national coverage policy for renal denervation procedures. This analysis was started after Medtronic requested it to help Medicare beneficiaries access the Symplicity™ Spyral renal denervation system.
Medtronic plc has received European approval for the BrainSense™ Adaptive deep brain stimulation (aDBS) system, which is the first closed-loop DBS system that adjusts brain stimulation in real-time for Parkinson's disease patients. This approval, known as CE Mark, confirms that the device meets the EU Medical Device Regulation standards. The initial programming of the system was successfully carried out by Dr. Martijn Beudel, a neurologist from Amsterdam University Medical Center.
FAQ
- What is the primary business of Medtronic?
- What is the ticker symbol for Medtronic?
- Does Medtronic pay dividends?
- What sector is Medtronic in?
- What industry is Medtronic in?
- What country is Medtronic based in?
- When did Medtronic go public?
- Is Medtronic in the S&P 500?
- Is Medtronic in the NASDAQ 100?
- Is Medtronic in the Dow Jones?
- When was Medtronic's last earnings report?
- When does Medtronic report earnings?
- Should I buy Medtronic stock now?